Coccidioidomycosis in persons infected with HIV type 1

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Coccidioidomycosis is a recognized opportunistic infection among persons infected with human immunodeficiency virus (HIV). Early in the HIV epidemic, most cases presented as overwhelming diffuse pulmonary disease with a high mortality rate. Although these cases are still seen, patients without significant immunodeficiency frequently present with a community-acquired pneumonia syndrome. Diagnosis can be established by cytological staining, culture, or serologic testing. All patients with HIV infection and symptomatic coccidioidomycosis should be treated with antifungal therapy. Severe cases frequently require a combination of therapy with amphotericin B and a triazole antifungal. Therapy for at least 1 year is recommended, but for patients with a focal pulmonary infection and peripheral blood CD4 lymphocyte counts of >250 cells/μL, it may be reasonable to stop therapy after this time. Other manifestations of coccidioidomycosis require prolonged therapy, and life-long treatment is recommended for persons with meningitis.

Original languageEnglish (US)
Pages (from-to)1174-1178
Number of pages5
JournalClinical Infectious Diseases
Volume41
Issue number8
DOIs
StatePublished - Oct 15 2005

Fingerprint

Coccidioidomycosis
HIV-1
HIV
Therapeutics
Focal Infection
Triazoles
Opportunistic Infections
Amphotericin B
Virus Diseases
CD4 Lymphocyte Count
Meningitis
Lung Diseases
Pneumonia
Staining and Labeling
Lung
Mortality

ASJC Scopus subject areas

  • Immunology

Cite this

Coccidioidomycosis in persons infected with HIV type 1. / Ampel, Neil M.

In: Clinical Infectious Diseases, Vol. 41, No. 8, 15.10.2005, p. 1174-1178.

Research output: Contribution to journalArticle

@article{c396bc61fac240c6bcc8459694c6b733,
title = "Coccidioidomycosis in persons infected with HIV type 1",
abstract = "Coccidioidomycosis is a recognized opportunistic infection among persons infected with human immunodeficiency virus (HIV). Early in the HIV epidemic, most cases presented as overwhelming diffuse pulmonary disease with a high mortality rate. Although these cases are still seen, patients without significant immunodeficiency frequently present with a community-acquired pneumonia syndrome. Diagnosis can be established by cytological staining, culture, or serologic testing. All patients with HIV infection and symptomatic coccidioidomycosis should be treated with antifungal therapy. Severe cases frequently require a combination of therapy with amphotericin B and a triazole antifungal. Therapy for at least 1 year is recommended, but for patients with a focal pulmonary infection and peripheral blood CD4 lymphocyte counts of >250 cells/μL, it may be reasonable to stop therapy after this time. Other manifestations of coccidioidomycosis require prolonged therapy, and life-long treatment is recommended for persons with meningitis.",
author = "Ampel, {Neil M.}",
year = "2005",
month = "10",
day = "15",
doi = "10.1086/444502",
language = "English (US)",
volume = "41",
pages = "1174--1178",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Coccidioidomycosis in persons infected with HIV type 1

AU - Ampel, Neil M.

PY - 2005/10/15

Y1 - 2005/10/15

N2 - Coccidioidomycosis is a recognized opportunistic infection among persons infected with human immunodeficiency virus (HIV). Early in the HIV epidemic, most cases presented as overwhelming diffuse pulmonary disease with a high mortality rate. Although these cases are still seen, patients without significant immunodeficiency frequently present with a community-acquired pneumonia syndrome. Diagnosis can be established by cytological staining, culture, or serologic testing. All patients with HIV infection and symptomatic coccidioidomycosis should be treated with antifungal therapy. Severe cases frequently require a combination of therapy with amphotericin B and a triazole antifungal. Therapy for at least 1 year is recommended, but for patients with a focal pulmonary infection and peripheral blood CD4 lymphocyte counts of >250 cells/μL, it may be reasonable to stop therapy after this time. Other manifestations of coccidioidomycosis require prolonged therapy, and life-long treatment is recommended for persons with meningitis.

AB - Coccidioidomycosis is a recognized opportunistic infection among persons infected with human immunodeficiency virus (HIV). Early in the HIV epidemic, most cases presented as overwhelming diffuse pulmonary disease with a high mortality rate. Although these cases are still seen, patients without significant immunodeficiency frequently present with a community-acquired pneumonia syndrome. Diagnosis can be established by cytological staining, culture, or serologic testing. All patients with HIV infection and symptomatic coccidioidomycosis should be treated with antifungal therapy. Severe cases frequently require a combination of therapy with amphotericin B and a triazole antifungal. Therapy for at least 1 year is recommended, but for patients with a focal pulmonary infection and peripheral blood CD4 lymphocyte counts of >250 cells/μL, it may be reasonable to stop therapy after this time. Other manifestations of coccidioidomycosis require prolonged therapy, and life-long treatment is recommended for persons with meningitis.

UR - http://www.scopus.com/inward/record.url?scp=26444467686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444467686&partnerID=8YFLogxK

U2 - 10.1086/444502

DO - 10.1086/444502

M3 - Article

VL - 41

SP - 1174

EP - 1178

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 8

ER -